Znn3bq.jpeg
²é¿´: 3028  |  »Ø¸´: 4
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

niebiao2008

ÖÁ×ðľ³æ (ÖøÃûдÊÖ)

study

[½»Á÷] CMC²ÄÁÏ׫дģ°å ÒÑÓÐ4È˲ÎÓë

CMC²ÄÁÏ׫дģ°å

Chemistry, Manufacturing and Controls



S DRUG SUBSTANCEÔ­ÁÏÒ©

S.1 General Information»ù±¾ÐÅÏ¢

S.1.1 NomenclatureÒ©Æ·Ãû³Æ

² International Nonproprietary NameͨÓÃÃû

² Chemical name»¯Ñ§Ãû

² Chemical Abstracts Service Registry Number CASºÅ

S.1.2 Structure½á¹¹

² structural formula (stereochemistry)½á¹¹Ê½£¨Á¢Ìå¹¹ÐÍ£©

² molecular formula·Ö×Óʽ

² molecular weight·Ö×ÓÁ¿

² amino acid sequence°±»ùËáÐòÁÐ

S.1.3 General PropertiesÀí»¯ÐÔÖÊ£¨ÁÐ±í£©

² general description (appearance, color, physical state)ÐÔ×´£¨Íâ¹Û¡¢ÑÕÉ«¡¢Îï̬£©

² melting or boiling pointsÈÛµã»ò·Ðµã

² optical rotation±ÈÐý¶È

² solubility profileÈܽâÐÔ

² solution pHÈÜÒºpH

² partition coefficients·ÖÅäϵÊý

² dissociation constants½âÀë³£Êý

² physical form (polymorph, solvate, hydrate)ÎïÖÊÐÎʽ£¨¶à¾§ÐÍÎï¡¢ÈܼÁ»¯ÎˮºÏÎ

² hygroscopicityÒýʪÐÔ

² particle size¿ÅÁ£¶È

S.2 ManufactureÉú²úÐÅÏ¢

S.2.1 ManufacturersÉú²úÉÌ

² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»postcodeÓʱࣻtelephone numberµç»°ºÅÂ룻fax number´«ÕæºÅÂ룻contractorÁªÏµÈË£»e-mailµç×ÓÓÊÏä

S.2.2 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ

S.2.2.1 Flow DiagramºÏ³É·Ïßͼ/¹¤ÒÕÁ÷³Ìͼ

S.2.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö

S.2.2.3 Reprocessing, Reworking, Recycling, Regeneration, and Other Operations·µ¹¤

S.2.3 Control of MaterialsÎïÁÏ¿ØÖÆ

S.2.3.1 Starting MaterialsÆðʼԭÁÏ

S.2.3.2 Reagents, Solvents, and Auxiliary MaterialsÊÔ¼Á¡¢ÈܼÁ¡¢¸¨Öú²ÄÁÏ

S.2.3.3 DiluentsÏ¡ÊͼÁ

S.2.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ

S.2.4.1 Critical Steps and Critical Operating Parameters¹Ø¼ü²½Öè¼°¹Ø¼ü¹¤ÒÕ²ÎÊý

S.2.4.2 Controls of IntermediatesÖмäÌå¿ØÖÆ

S.2.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û

S.2.6 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢

² ºÏ³É·ÏßµÄÑ¡ÔñºÍÓÅ»¯

² ¹Ø¼ü¹¤ÒÕ²ÎÊýµÄÈ·¶¨

² ¹¤ÒÕ·Å´óÑо¿

S.3 CharacterizationÌØÐÔ¼ø¶¨

S.3.1 Elucidation of Structure and Other Characteristics½á¹¹ºÍÀí»¯ÐÔÖÊ

S.3.1.1 Elucidation of Structure½á¹¹È·Ö¤

² elemental analysisÔªËØ·ÖÎö£»MSÖÊÆ×£»NMR spectroscopyºË´ÅͼÆ×£»UV spectroscopy×ÏÍâ¹âÆ×£»IR spectroscopyºìÍâ¹âÆ×

S.3.1.2 Physicochemical CharacterizationÀí»¯ÐÔÖÊ

² X-ray diffraction (single crystal or powder)XÉäÏßÑÜÉ䣨µ¥¾§»ò·ÛÄ©£©£»particle size analysis¿ÅÁ£¶È·ÖÎö£»DSCʾ²îɨÃèÁ¿ÈÈ·¨£»FTIR¸µÁ¢Ò¶×ª»»ºìÍâÏß¹âÆ×£»TGAÈÈÖØ·ÖÎö

S.3.1.3 Biological and Other Relevant CharacteristicsÆäËûÐÔÖÊ

S.3.2 ImpuritiesÔÓÖÊ

² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼

S.4 Control of Drug SubstanceÔ­ÁÏÒ©µÄÖÊÁ¿¿ØÖÆ

S.4.1 SpecificationÖÊÁ¿±ê×¼£¨ÁÐ±í£©

² tests¼ì²âÏîÄ¿£ºappearanceÍâ¹Û£»identification tests¼ø±ð£»melting rangeÈ۳̣»residue on ignition³ãׯ²ÐÔü£»heavy metalsÖØ½ðÊô£»specified impuritiesÓйØÎïÖÊ£»unspecified impurities·ÇÌØ¶¨ÔÓÖÊ£»total organic impurities×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»particle size distributionÁ£¾¶·Ö²¼£¨D10¡¢D50¡¢D90£©£»water contentË®·Ö£»¶ÔÓ³Òì¹¹Ì壻º¬Á¿²â¶¨

² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ

² analytical procedure·½·¨£ºHPLC£»GC

S.4.2 Analytical Procedures·ÖÎö·½·¨£¨ÆóÒµ·½·¨£©

² º¬Á¿¼ì²â·½·¨

² ÓйØÎïÖʼì²â·½·¨

² ¶ÔÓ¦Òì¹¹Ìå¼ì²â·½·¨

² ²ÐÁôÈܼÁ¼ì²â·½·¨

S.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤

² רÊôÐÔ£»¼ì²âÏÞ£»¶¨Á¿ÏÞ£»ÏßÐԺͷ¶Î§£»¾«Ãܶȣ»×¼È·¶È£»ÄÍÓÃÐÔ

S.4.4 Batch AnalysesÅú¼ìÑ鱨¸æ

Åú´Î1£»Åú´Î2£»Åú´Î3

S.4.5 Justification of SpecificationÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý

S.5 Reference Standards or Materials¶ÔÕÕÆ·

S.6 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷

S.7 StabilityÎȶ¨ÐÔ

S.7.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá

S.7.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ

S.7.3 Stability DataÎȶ¨ÐÔÊý¾Ý



P DRUG PRODUCTÖÆ¼Á

P.1 Description and Composition of the Drug Product¼ÁÐͼ°²úÆ·×é³É

² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼

P.2 Pharmaceutical Development²úÆ·¿ª·¢

P.2.1 Components of the Drug Product´¦·½×é³É

P.2.1.1 Drug SubstanceÔ­ÁÏÒ©

² the compatibility of the drug substance with the excipientsÔ­ÁÏÒ©Ó븨ÁϵÄÏàÈÝÐÔ

² key physicochemical characteristicsÖØÒªÀí»¯ÐÔÖÊ

P.2.1.2 Excipients¸¨ÁÏ

² the choice of excipients¸¨ÁÏÖÖÀàµÄÑ¡Ôñ

² concentration of excipients¸¨ÁϵÄÓÃÁ¿

P.2.2 Drug ProductÖÆ¼ÁÑо¿

P.2.2.1 Formulation Development´¦·½¿ª·¢¹ý³Ì

P.2.2.2 Overages¹ýÁ¿

P.2.2.3 Physicochemical and Biological PropertiesÀí»¯ÌØÐÔºÍÉúÎïÑ§ÌØÐÔ

P.2.3 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢

P.2.4 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷

² the suitability of the container closure system°ü×°²ÄÁϺÍÈÝÆ÷µÄºÏÊÊÐÔ

P.2.5 Microbiological Attributes΢ÉúÎïÐÔÖÊ

P.2.6 CompatibilityÏàÈÝÐÔ

² the compatibility of the drug product with reconstitution diluents or dosage devices

P.3 ManufactureÉú²úÐÅÏ¢

P.3.1 ManufacturersÉú²úÉÌ

² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»contractorÁªÏµÈË

P.3.2 Batch FormulaÅú´¦·½

² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼

P.3.3 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ

P.3.2.1 Flow Diagram¹¤ÒÕÁ÷³Ìͼ

P.3.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö

P.3.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ

P.3.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û

² ¹¤ÒÕÑéÖ¤·½°¸

² ¹¤ÒÕÑéÖ¤±¨¸æ

P.4 Control of Excipients¸¨ÁϵĿØÖÆ

P.4.1 SpecificationsÖÊÁ¿±ê×¼

P.4.2 Analytical Procedures·ÖÎö·½·¨

P.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤

P.4.4 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý

P.4.5 Excipients of Human or Animal OriginÈËÔ´»ò¶¯ÎïÔ´¸¨ÁÏ

P.4.6 Novel Excipientsи¨ÁÏ

P. 5 Control of Drug ProductÖÆ¼ÁµÄÖÊÁ¿¿ØÖÆ

P.5.1 SpecificationsÖÊÁ¿±ê×¼

² tests¼ì²éÏîÄ¿£ºdescriptionÐÔ×´£»identification test¼ø±ð£»core weightÖØÁ¿²îÒ죻dissolutionÈܳö¶È£»water contentË®·Ö£»specified degradation productsÓйØÎïÖÊ£»unspecified degradation product·ÇÌØ¶¨ÔÓÖÊ£»total degradation products×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»Î¢ÉúÎïÏÞ¶È£»º¬Á¿²â¶¨

² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ

² analytical procedure·½·¨£ºHPLC£»GC

P.5.2 Analytical Procedures·ÖÎö·½·¨

² º¬Á¿²â¶¨·½·¨

² ÓйØÎïÖʼì²â·½·¨

² Èܳö¶È²â¶¨·½·¨

² ÖØÁ¿²îÒì²â¶¨·½·¨

² ΢ÉúÎïÏ޶ȼì²é·½·¨

P.5.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤

² ²¨³¤Ñ¡Ôñ£»×¨ÊôÐÔ£»ÏµÍ³ÊÊÓÃÐÔ£»¼ì²âÏÞ£»ÈÜÒºÎȶ¨ÐÔ£»ÄÍÓÃÐÔ£»ÏßÐÔÓ뷶Χ£»¶¨Á¿ÏÞ£»»ØÊÕÂÊ£»¾«Ãܶȣ»×¼È·¶È

P.5.4 Batch AnalysesÅú¼ìÑ鱨¸æ

Åú´Î1£»Åú´Î2£»Åú´Î3

P.5.5 Characterization of ImpuritiesÔÓÖÊ·ÖÎö

² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼

P.5.6 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý

P.6 Reference Standards or Materials¶ÔÕÕÆ·

P.7 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷

P.8 StabilityÎȶ¨ÐÔ

P.8.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá

P.8.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ

² °ü×°²ÄÁÏ

² Öü²ØÌõ¼þ

² ÓÐЧÆÚ

P.8.3 Stability DataÎȶ¨ÐÔÊý¾Ý

² Ó°ÏìÒòËØÊÔÑ飨¸ßΡ¢¸ßʪ¡¢¹âÕÕ£©

² ¼ÓËÙÊÔÑé

² ³¤ÆÚÊÔÑé
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ÎáÖ®µÀ ¸ÐÐËȤµÄ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

²»¶Ïѧϰ,²»¶Ï½ø²½!
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÃÎäìÏæ

ľ³æ (ÖøÃûдÊÖ)


¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
×ªÔØÇë×¢Ã÷³ö´¦£¬ÕâÖ»ÊÇÎÒÕûÀíµÄ³õ¸å£¬ÀïÃæÈ±Á˲»ÉÙ¶«Î÷¡£
4Â¥2013-05-23 19:23:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 5 ¸ö»Ø´ð

YBMCL

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ºÜºÃ£¬Â¥Ö÷ÄÜ·ñ¸ø¸öword¸ñʽµÄÄØ£¿Ð»Ð»£¡
2Â¥2013-05-23 15:41:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

cjtyyh

Òø³æ (СÓÐÃûÆø)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
·Ç³£ºÃ£¬Ö§³ÖÂ¥Ö÷£¬Ëæ×ÅÖÆ¼Á¹ú¼Ê»¯·¢Õ¹£¬Õâ·Ý×ÊÁÏÖ¸µ¼ÒâÒåÔ½À´Ô½´ó
3Â¥2013-05-23 16:19:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

triassic

Í­³æ (³õÈëÎÄ̳)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
thank you very much! really really helpful!
5Â¥2013-07-14 14:49:56
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸085802 323·ÖÇóµ÷¼Á +12 drizzle_9 2026-04-12 13/650 2026-04-13 01:15 by ÐÒÃâ ..
[¿¼ÑÐ] Çóµ÷¼Á£¬985²ÄÁÏÓ뻯¹¤348·Ö +9 º­ÖñÁõ 2026-04-11 13/650 2026-04-12 22:40 by º­ÖñÁõ
[¿¼ÑÐ] µ÷¼Á +25 ²»·ê´º 2026-04-07 26/1300 2026-04-12 11:53 by ´óÁ¦Ë®ÊÖÁ¦´óÎÞÇ
[¿¼ÑÐ] Çóµ÷¼Á£¬262»úеר˶ +8 àÅyyl 2026-04-08 8/400 2026-04-12 02:31 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤300Çóµ÷¼Á +39 Ф¿ªÎÄ 2026-04-09 43/2150 2026-04-12 01:30 by Çï¶¹²ËÑ¿
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£ÖÝ´óѧ 22408 305·ÖÇóµ÷¼Á +5 °²Ð¡Âúzzz 2026-04-08 5/250 2026-04-12 00:41 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 299Çóµ÷¼Á +8 ZVVZ13 2026-04-08 8/400 2026-04-12 00:40 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Ò»Ö¾Ô¸¾©Çø985£¬085401µç×ÓÐÅÏ¢£¬±¾¿Æµç×ÓÐÅÏ¢ +3 Ñô¹â¿ªÀʵÄÄк¢ 2026-04-10 3/150 2026-04-10 16:29 by sophia_93
[¿¼ÑÐ] Ò»Ö¾Ô¸0703»¯Ñ§ÕÐ61×îÖÕÅÅÃû62»¯Ñ§Çóµ÷¼Á +24 ÕÐ61ÅÅÃû62 2026-04-07 28/1400 2026-04-10 16:15 by yx54321
[¿¼ÑÐ] ¿¼ÑжþÂÖµ÷¼Á +8 ¹ÊÈË?? 2026-04-09 8/400 2026-04-10 09:44 by Çà÷duoduo
[¿¼ÑÐ] 085601³õÊÔ330·ÖÕÒµ÷¼Á +10 Á÷ÐÄÄ̻ưül 2026-04-09 10/500 2026-04-10 08:14 by Sammy2
[¿¼ÑÐ] 284Çóµ÷¼Á +7 ÈÃÎÒÉϰ¶°É°¢Î÷ 2026-04-09 7/350 2026-04-09 18:59 by haironglove
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +21 ²»ÖªÃûµÄСئ 2026-04-08 21/1050 2026-04-09 18:55 by l_paradox
[¿¼ÑÐ] Ò»Ö¾Ô¸Öйú¿ÆÑ§ÔºÉϺ£ÓлúËù£¬Óлú»¯Ñ§356·ÖÕÒµ÷¼Á +11 Nadiums 2026-04-09 11/550 2026-04-09 18:04 by lijunpoly
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤289·Ö +31 ˶ÐǸ° 2026-04-08 31/1550 2026-04-09 16:54 by Delta2012
[¿¼ÑÐ] ²ÄÁϹ¤³Ì322 +18 ¹þ¹þ¹þºðºðºð¹þ 2026-04-07 19/950 2026-04-09 10:44 by cymywx
[¿¼ÑÐ] »úе¹¤³Ì264ѧ˶Çóµ÷¼Á +3 qiushangxian 2026-04-06 3/150 2026-04-08 01:53 by Linzejun
[¿¼ÑÐ] 318Çóµ÷¼Á +5 ÀîÇàɽɽɽ 2026-04-07 5/250 2026-04-07 18:24 by À¶ÔÆË¼Óê
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +17 СÁõͬѧ߹߹ 2026-04-06 18/900 2026-04-07 11:41 by Ê«Óë×ÔÓÉ
[¿¼ÑÐ] 312Çóµ÷¼Á +4 LR6 2026-04-06 4/200 2026-04-07 08:42 by jp9609
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û